Tirabrutinib - Ono Pharmaceutical/Gilead Sciences

Drug Profile

Tirabrutinib - Ono Pharmaceutical/Gilead Sciences

Alternative Names: GS-4059; ONO-4059

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ono Pharmaceutical
  • Developer Gilead Sciences; Ono Pharmaceutical
  • Class Antineoplastics; Purines; Pyrrolidines; Small molecules
  • Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Chronic lymphocytic leukaemia; Sjogren's syndrome
  • Phase I/II Lymphoma
  • Phase I Autoimmune disorders; B cell lymphoma; Rheumatoid arthritis

Most Recent Events

  • 02 Feb 2018 Phase-I clinical trials in Autoimmune disorders in Japan (PO) (Ono Pharmaceutical pipeline, February 2018)
  • 01 Jul 2017 Phase-I/II clinical trials in Lymphoma (Refractory metastatic disease, Monotherapy, Second-line therapy or greater) in Japan (PO) (JapicCTI-173646)
  • 02 Jun 2017 Efficacy and adverse events data from a phase Ib trial in B-cell lymphoma (Combination therapy, Second-line therapy or greater) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top